SCHEMBL3532297

SCHEMBL3532297

CCOC(=O)c1cn(C2CCCC2)c2nc(S(C)(=O)=O)ncc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
XBP1 P17861 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TLR9 Q9NR96 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
CSF1R P07333 5/20 0.41
BTK Q06187 1/20 0.40
CSNK1D P48730 1/20 0.39
ELANE P08246 1/20 0.38
PDE4B Q07343 2/20 0.38
ADRB2 P07550 1/20 0.38
HPGD P15428 1/20 0.37
CDK4 P11802 1/20 0.37
CDK6 Q00534 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3293567 0.99 NPC1 (0.43) ALDH1A1NPC1TP53MAPTXBP1
SCHEMBL3530039 0.83 CSF1R (0.45) ALDH1A1NPC1TP53MAPTXBP1
SCHEMBL3530643 0.83 MEN1 (0.50) ALDH1A1MAPTCSF1RCSNK1DELANE
SCHEMBL3290260 0.82 KMT2A (0.49) ALDH1A1MAPTCSF1RCSNK1DPDE4B
SCHEMBL10987423 0.81 ADRB2 (0.42) ALDH1A1MAPTCSF1RCSNK1DELANE
SCHEMBL10993730 0.79 CASP1 (0.55) MAPTCSF1RPDE4BADRB2POLB
SCHEMBL10991468 0.78 RAB9A (0.42) ALDH1A1NPC1MAPTMAPK1HSD17B10
SCHEMBL3291298 0.78 CSF1R (0.50) ALDH1A1CSF1RADRB2CDK4CDK6
SCHEMBL3293573 0.77 CSF1R (0.44) ALDH1A1NPC1TP53MAPTXBP1
SCHEMBL3293197 0.77 CSF1R (0.49) CSF1RADRB2CDK4CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR ALDH1A1 3590/4885NPC1 4554/4885TP53 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.